Company Overview

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for retinal diseases, particularly chronic and high-prevalence conditions affecting vision. The company operates within the biotechnology and ophthalmology industries, with an emphasis on biologic therapies designed for extended durability. Kodiak’s core strategy centers on its proprietary Antibody Biopolymer Conjugate (ABC) platform, which is intended to enable longer-acting intravitreal therapies and reduce treatment burden for patients.

The company’s primary historical revenue drivers have been collaboration revenue and interest income, as Kodiak has not yet commercialized a product. Its lead clinical programs have targeted wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), large and well-established retinal markets. Kodiak was founded in 2009 and completed its initial public offering in 2020, evolving from a platform-focused research organization into a late-stage clinical development company with multiple retinal assets.

Business Operations

Kodiak operates as a single-reportable-segment biotechnology company, generating no product revenue to date and funding operations primarily through equity financing and prior collaboration arrangements. Its research and development activities are centered on advancing biologic candidates built on the ABC platform, which combines antibody therapeutics with biopolymer conjugation to extend intraocular durability. The company’s most advanced clinical candidate historically was KSI-301 (tarcocimab tedromer), which progressed through multiple Phase 3 trials.

Operations are primarily conducted internally, with clinical trials managed through a network of global clinical research organizations. Kodiak does not manufacture products at commercial scale and relies on third-party manufacturers for clinical supply. The company has maintained selective strategic collaborations, including prior research and development arrangements with large pharmaceutical companies, though no active revenue-generating partnerships have been disclosed in recent filings.

Strategic Position & Investments

Kodiak’s strategic direction has shifted toward pipeline prioritization and capital preservation following mixed Phase 3 clinical outcomes for tarcocimab. The company has reoriented resources toward earlier-stage and next-generation retinal programs leveraging lessons learned from its initial platform validation efforts. Public disclosures indicate a focus on new molecular designs intended to improve efficacy and durability in retinal indications.

The company has not completed any transformational acquisitions and does not operate a diversified portfolio of subsidiaries. Investments are primarily internal and directed toward R&D, clinical trials, and platform refinement. Kodiak’s positioning remains that of a platform-driven retinal innovator, competing with both large pharmaceutical companies and emerging biotechnology firms in the ophthalmology space.

Geographic Footprint

Kodiak Sciences is headquartered in Palo Alto, California, within the United States, and conducts the majority of its research, development, and corporate operations domestically. Clinical trials for its retinal programs have been conducted across North America, Europe, and parts of Asia-Pacific, reflecting the global prevalence of retinal diseases and regulatory requirements for late-stage development.

While the company does not maintain international commercial operations, its clinical and regulatory activities give it an operational footprint across multiple continents. Kodiak does not currently report material revenue from international markets and has no foreign manufacturing facilities disclosed in public filings.

Leadership & Governance

Kodiak is led by an executive team with experience in biotechnology, ophthalmology, and capital markets. The company emphasizes a science-driven and data-centric leadership philosophy, with strategic decisions closely tied to clinical outcomes and regulatory feedback. Governance follows U.S. public company standards, with oversight by an independent board of directors and compliance with SEC reporting requirements.

Key executives include:

• Victor Perlroth – Chief Executive Officer
• Vito J. Palombella – Chief Scientific Officer
• Ramin Tadayoni – Chief Medical Officer
• Trent Clark – Chief Financial Officer
• Ellen Schuler – Chief Legal Officer and Corporate Secretary

Kodiak’s leadership has publicly emphasized disciplined capital allocation, portfolio focus, and scientific rigor following recent clinical readouts, aligning governance practices with long-term shareholder and patient considerations.